论文部分内容阅读
产后出血是产科常见且严重的并发症之一,是我国目前孕产妇死亡的首要原因。而宫缩乏力性出血又是产后出血的首要原因。因此,积极防治子宫收缩乏力性出血,是降低孕产妇死亡率的关键。目前治疗产后出血,除了用机械性和物理方法刺激子宫收缩外,药物只有催产素及麦角新硷。在这些方法都不能奏效时,往往只能行子宫切除术,有时失血性休克成为不可逆时,仍会危及产妇的生命。自1976年Takagi首次所用PGF2a治疗产后出血以来,国内亦相继有这方面的报道。我院自1985年就已开始将前列腺素的衍生物15-甲基PGF2a用于产后出血的治疗,效果满意,有临床推广及应用价值,现介绍如下。
Postpartum hemorrhage is one of the common and serious complication of obstetrics, and is the primary cause of maternal death in our country. The uterine inert bleeding is the primary cause of postpartum hemorrhage. Therefore, active prevention and treatment of uterine atony bleeding is the key to reduce maternal mortality. The current treatment of postpartum hemorrhage, in addition to using mechanical and physical methods to stimulate uterine contraction, the drug only oxytocin and ergometrine. When none of these methods work, often only hysterectomy can be performed, sometimes hemorrhagic shock becomes irreversible, it can endanger the lives of mothers. Since 1976, Takagi PGF2a used for the first time since the treatment of postpartum hemorrhage, have also been reported in China. Our hospital has been started since 1985, the prostaglandin derivative 15-methyl PGF2a for the treatment of postpartum hemorrhage, with satisfactory results, clinical application and promotion, are described below.